Italy· 042292021
ABRIFF*sosp inal 120 dosi 125 mcg + 5 mcg
A medicinal product containing fluticasone/formoterolo, registered in Italy by MUNDIPHARMA PHARMACEUTIC. Srl, on the national reimbursement list.
Checked against the register on
Informational only — not a medical device.
The record
At a glance
- Active substance
- Fluticasone/formoterolo
- Manufacturer
- MUNDIPHARMA PHARMACEUTIC. Srl
- Country
- Italy (IT)
- ATC code
- —
- Reimbursed
- Yes
- Last checked
- June 4, 2026
Packs & prices · 1
1 priced- aic042292021ABRIFF*sosp inal 120 dosi 125 mcg + 5 mcgEUR 50.17
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9906bc16-7f1b-4584-be17-0ad8f435dbf9 GET /v1/drugs/9906bc16-7f1b-4584-be17-0ad8f435dbf9?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"price": 50.17,
"source": "aifa",
"currency": "EUR",
"strength": "FLUTICASONE+FORMOTEROLO 125+5MCG 120 UNITA' USO RESPIRATORIO",
"substance": "Fluticasone/formoterolo",
"equivalence_group": "BQX",
"transparency_flag": null
}See everything about fluticasone/formoterolo.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.